ArticleFrontiers in immunology2026
Immunotherapy plus induction chemotherapy followed by radiotherapy alone or one cycle of concurrent chemotherapy with cisplatin vs induction chemotherapy followed by two cycles of concurrent chemotherapy with cisplatin in locoregionally advanced nasopharyngeal carcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare the efficacy and safety of immunotherapy combined with induction chemotherapy followed by radiotherapy alone or one cycle of concurrent chemoradiotherapy with cisplatin versus induction chemotherapy followed by two cycles of concurrent chemoradiotherapy with cisplatin in patients with locally advanced nasopharyngeal carcinoma. Methods: A total of 173 patients with locally advanced nasopharyngeal carcinoma treated at our hospital from November 2019 to September 2024 were retrospectively analyzed. Patients received induction therapy with immunotherapy (toripalimab or tislelizumab) combined with chemotherapy (TPC or GP) followed by radiotherapy alone or one cycle of concurrent chemoradiotherapy with cisplatin (immunochemotherapy group). Patients received TPC or GP induction chemotherapy followed by 2 cycles of concurrent chemoradiotherapy with cisplatin (IC-CCRT group). Immunotherapy was given on day 1 of each cycle of induction therapy. The efficacy and toxicities of the two groups were evaluated. Results: After induction therapy, 20 patients (29.4%) in the immunochemotherapy group and 15 patients (14.3%) in the IC-CCRT group achieved complete remission (p=0.02). At a median follow-up of 27.5 months, recurrence or metastasis occurred in 7.4%(5/68) of the patients in the immunochemotherapy group and 19.0%(20/105) of those in the IC-CCRT group. The 2-year event-free survival (EFS), overall survival (OS), locoregional recurrence-free survival (LRRFS) and distant metastasis-free survival (DMFS) in the immunochemotherapy group were 93.5% vs 81.1% (p=0.03), 100.0% vs 97.9% (p=0.3), 96.9% vs 91.4% (p=0.2), 95.0% vs 88.2% (p=0.1) compared with the IC-CCRT group. There were 28 cases (41.1%) in the immunochemotherapy group and 58 cases (55.2%) in the IC-CCRT group experienced grade 3-4 acute adverse events. In the immunochemotherapy group, 4 patients developed grade 3-4 immune-related adverse events. Conclusions: Compared with induction chemotherapy followed by two cycles of concurrent chemoradiotherapy with cisplatin, immunotherapy combined with induction chemotherapy followed by radiotherapy alone or one cycle of concurrent chemoradiotherapy with cisplatin may improve the EFS of patients with locally advanced nasopharyngeal carcinoma with low adverse events. However, this data requires prospective randomized controlled studies to be confirmed in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.